

RESEARCH

Open Access

Treg cells mediate recovery from EAE by controlling effector T cell proliferation and motility in the CNS

Michail Koutrolos¹, Kerstin Berer¹, Naoto Kawakami^{1,2}, Hartmut Wekerle¹ and Gurumoorthy Krishnamoorthy^{1*}

Abstract

Regulatory T cells are crucial in controlling various functions of effector T cells during experimental autoimmune encephalomyelitis. While regulatory T cells are reported to exert their immunomodulatory effects in the peripheral immune organs, their role within the central nervous system (CNS) during experimental autoimmune encephalomyelitis is unclear. Here, by combining a selectively timed regulatory T cells depletion with 2-photon microscopy, we report that regulatory T cells exercise their dynamic control over effector T cells in the CNS. Acute depletion of regulatory T cells exacerbated experimental autoimmune encephalomyelitis severity which was accompanied by increased pro-inflammatory cytokine production and proliferation of effector T cells. Intravital microscopy revealed that, in the absence of regulatory T cells, the velocity of effector T cells was decreased with simultaneous increase in the proportion of stationary phase cells in the CNS. Based on these data, we conclude that regulatory T cells mediate recovery from experimental autoimmune encephalomyelitis by controlling cytokine production, proliferation and motility of effector T cells in the CNS.

Keywords: Regulatory T cells, 2-photon imaging, Experimental autoimmune encephalomyelitis

Introduction

CD4⁺Foxp3⁺ regulatory T cells (T_{reg}) have a well-characterized role in promoting peripheral immunological tolerance throughout life by suppressing deleterious inflammatory responses [1]. Lack of T_{reg} due to mutations in the FOXP3 gene in humans results in aggressive multi-organ autoimmunity called IPEX (immunodysregulation, polyendocrinopathy, enteropathy, X-linked) syndrome [2]. Similarly, *scurfy* mice, which harbor mutations in the *Foxp3* gene, or *Foxp3*-gene deficient mice suffer from a massive lymphoproliferative syndrome [3,4]. Targeted depletion of T_{reg} also resulted in severe multi-organ autoimmunity [5,6]. Intriguingly, however, no spontaneous central nervous system (CNS) inflammation was observed in *Foxp3* mutant mice or after targeted depletion of *Foxp3*+T_{reg} cells in wild type mice [7].

T_{reg} have been demonstrated to be capable of controlling CNS autoimmunity in several Experimental Autoimmune

Encephalomyelitis (EAE) models. The frequencies of T_{reg} population within the CNS were elevated during the recovery phase of actively induced EAE [8-10]. Moreover, several studies described that the transfer of CD25⁺ T_{reg} ameliorated EAE symptoms [9,11-13]. In addition, non-specific ablation of natural T_{reg} by anti-CD25 antibodies has been reported to exacerbate EAE [9,14-16]. Furthermore, T_{reg} have been shown to prevent spontaneous EAE development [17,18] or delay spontaneous EAE onset [19].

Where and how do T_{reg} exert their control over myelin-specific T cells? In principle, T_{reg} could suppress effector T cells (T_{eff}) in the periphery or within the target organ, CNS. One report demonstrated that T_{reg} accumulate in the CNS at the peak of EAE but were unable to suppress CNS-derived T_{eff} *in vitro* [8]. In contrast, T_{reg} isolated from the recovery phase of the disease were still capable of suppressing T_{eff} [10]. Furthermore, another study reported that, in the absence of T_{reg}, there is an enhanced migration of T_{eff} from the periphery [19]. T_{reg} are known to limit the inflammatory reactions using several mechanisms that include soluble mediators, cell-to-cell contact with T_{eff} or inhibiting antigen presenting

* Correspondence: guru@neuro.mpg.de

¹Department of Neuroimmunology, Max Planck Institute of Neurobiology, Am Klopferspitz 18, 82152 Martinsried, Germany
Full list of author information is available at the end of the article

cells (APCs) [1]. T_{reg} influence EAE by affecting the priming and polarization of T_{eff} [11,20]. Among soluble cytokines produced by T_{reg} , IL-10 is important in containing T_{eff} proliferation *in vitro* [16]. T_{reg} can also set a threshold for activation of autoreactive T_{eff} by inhibiting their contacts with antigen-loaded dendritic cells (DCs) in the lymph nodes [21-23]. Furthermore, T_{reg} have been shown to contact and inhibit DCs *in vitro* via CTLA-4 [24]. However, the mode of action of T_{reg} during CNS autoimmunity, in particular within the target organ, still remains unclear.

To address those principal outstanding issues, in the present study, we combine targeted and acute depletion of T_{reg} with intravital two-photon microscopy to investigate the functional role of T_{reg} in the CNS during EAE. We found that T_{reg} limit autoimmune inflammation by controlling the T_{eff} proliferation and motility within the CNS.

Material and methods

Animals

DEREG [6] and T-Red [25] mice with the C57BL/6 genetic background were used. All mice were bred in the animal facility of the Max Planck Institute of Neurobiology and all experiments were conducted according to the guidelines of the committee on animals of the Max Planck Institute of Neurobiology and were approved by the Regierung von Oberbayern.

EAE induction and diphtheria toxin treatment

EAE was induced by injecting the mice subcutaneously into the flanks with 200 μ l of emulsion containing 200 μ g MOG₃₅₋₅₅ peptide (MEVGWYRSPFSRVVHLYRNGK) and 500 μ g *M. tuberculosis* strain H37 Ra (Difco) in incomplete Freund Adjuvant oil (Difco). In addition, the mice received 400 ng pertussis toxin (List Biological Laboratories) intraperitoneally (i.p.) on days 0 and 2 after immunization. Clinical signs of EAE were assessed daily according to the standard 5 point scale [26]. For depletion of T_{reg} in DEREG mice, diphtheria toxin (Sigma-Aldrich) was injected both i.p. and i.v. (200 ng respectively) on day 4 post EAE onset.

Cell isolation and flow cytometry

Cells from lymph nodes and spinal cord were isolated as described before [26]. For detection of cell surface markers, cells were stained in FACS buffer (PBS containing 1% BSA and 0.1% NaN₃) with the following fluorochrome labeled monoclonal antibodies: anti-CD45 (30-F11), anti-CD4 (RM4-5), anti-CD25 (PC61) and anti-CD44 (IM7). For intracellular cytokine staining, cells were incubated for 16 hours with anti-CD3 (0.5 μ g/ml). Next, cells were fixed and permeabilized by incubation with Foxp3 Fixation/Permeabilization Buffer (eBioscience) and stained in Permeabilization Buffer (eBioscience) with the following

fluorochrome labeled monoclonal antibodies: anti-Foxp3 (FJK-16s), anti-IL-17 (eBio17B7) and anti-IFN γ (XMG1.2). All antibodies were purchased from BD Pharmingen or eBioscience. For cell number quantification, 10⁴ FACSuite FC Beads (BD) were added per sample prior to acquisition. Samples were acquired on FACS Verse (BD). FACS data were analyzed using FlowJo 7.6.5 software (TreeStar).

EdU proliferation assay

For *in vivo* proliferation experiments, 400 μ g EdU (Life Technologies) were injected i.p. to mice ~16 hours before their sacrifice. The Click-iT[®] EdU Alexa Fluor[®] 647 Flow Cytometry Assay Kit (Life Technologies) was used for staining for flow cytometry according to manufacturer's instructions.

Immunofluorescence

The organ sections were prepared as described previously [27]. The following monoclonal antibodies were used for staining: biotin-anti-CD4 (RM4-5; BD), Alexa Fluor 647-anti-CD11b (M1/70; Biolegend), Alexa Fluor 488-anti-Foxp3 (FJK-16 s; eBioscience), and Alexa Fluor 568-streptavidin (Invitrogen). Images were acquired on a SP5 confocal microscope (Leica), using 20x air-immersion (N.A. 0.70) or 63x oil-immersion (N.A. 1.4) objective. Images were processed using Image J (NIH) and Photoshop CS5 software (Adobe Systems).

In vivo IL-2 blocking

MOG₃₅₋₅₅/CFA-immunized DEREG B6 mice were treated with DTx, as described above. Purified anti-IL2 (JES6-1A12) monoclonal antibody or isotype control antibody (J1.2) was injected i.v. on day 4 (400 μ g) and day 6 (200 μ g) post EAE onset.

Intravital imaging

The technical setup of the 2-photon microscopy was as described before [28]. The pulsed laser was tuned to 880 nm and routed through a 25 \times water immersion objective (N.A. 0.95, Leica). Typically, a field of 360 \times 360 μ m was scanned, and 40–80 μ m z-stacks were acquired using a 3–6 μ m z-step. The acquisition rate was set to 25.219 s intervals, with images line-averaged twice. The fluorescence signals were detected using non-descanned photomultiplier tube (PMT) detectors (Hamamatsu) equipped with 525/50 nm (for detection of Alexa Fluor 488) and 630/69 nm (for detection of dsRedII) band-pass filters (Semrock). Mice were anesthetized and imaging in the spinal cord was performed as described previously [28]. For labeling of perivascular meningeal APC, we performed local instillation of Alexa Fluor 488-conjugated dextran (10 ng/ μ l, 10 kDa; Life Technologies) 20 min prior to imaging, as described before [29]. Image analysis was performed as described previously [29].

Statistical analysis

Statistical evaluations were performed as indicated in figure legends using GraphPad Prism software.

Results and discussion

Our approach to analyze the role of T_{reg} *in vivo* during EAE differs from previous attempts which have used anti-CD25 antibodies [9,14-16]. Since these antibodies persist in the circulation for long time, their effect on CD25-expressing activated T_{eff} cannot be excluded. To investigate the functional role of T_{reg} in the CNS during peak EAE, we chose DEREg mice which express a diphtheria toxin (DTx) receptor-enhanced GFP fusion protein, under the control of the *Foxp3* gene locus, permitting specifically timed depletion of T_{reg} by treatment with DTx [6]. We immunized DEREg mice with MOG₃₅₋₅₅ in CFA and treated them with DTx or PBS during peak of the disease. We monitored the efficiency of T_{reg} depletion in peripheral immune organs and the CNS by flow cytometry. Staining for Foxp3 revealed that T_{reg} population was almost completely absent in DTx-treated DEREg mice

compared to control animals in all the organs tested (Figure 1A,B). Next, immunized and treated mice were monitored daily for clinical score to assess the effect of T_{reg} depletion on EAE pathogenesis. While PBS-treated DEREg mice partially recovered from EAE, DTx-treated DEREg mice not only failed to recover from the disease, but also developed severe and, eventually, fatal EAE (Figure 1C). To rule out any adverse effect of DTx on EAE disease course, we have treated MOG₃₅₋₅₅ immunized wild type mice with DTx during peak EAE. Unlike in DEREg mice, the EAE course was not affected compared to control mice (Additional file 1: Figure S1). These findings suggest that T_{reg} contribute to recovery from EAE and perhaps have an essential function within the CNS.

To learn how T_{reg} ablation led to dramatic disease exacerbation, we stained spinal cord sections of the mice two days after the treatment with DTx or PBS. We observed highly increased numbers of T_{eff} as well as macrophages, in the spinal cord infiltrates in T_{reg} -depleted mice compared to the control animals (Figure 2A-F). Next, we quantified the numbers of $CD45^+CD4^+Foxp3^-$




Figure 1 Exacerbation of EAE after acute T_{reg} depletion at the peak of the disease. Representative flow cytometry plots (A) or mean frequency (\pm SEM) of Foxp3⁺ in CD45⁺CD4⁺ T cells (B) isolated from indicated organs of DEREg mice two days after DTx or PBS treatment are shown ($n = 11$ mice per group, pooled data from four independent experiments). (C) Mean clinical score (\pm SEM) of mice following immunization and DTx or PBS treatment (day 4 post EAE onset). ($n = 6-7$ mice per group, representative data from two independent experiments. ** $P < 0.01$, **** $P < 0.0001$, 2way ANOVA).




Figure 2 Increased numbers and enhanced proliferation of T_{eff} in T_{reg} -depleted mice. (A), (D) Representative panoramic pictures of spinal cord cryosections from mice treated with DTx (A) or PBS (D) stained with anti-Foxp3 (green), anti-CD4 (red) and anti-CD11b Ab (grey) (scale bar: 200 μ m). (B), (C), (E), (F) Magnified pictures of the indicated regions (A) and (D) (scale bar: 50 μ m). (G) Mean absolute numbers (\pm SEM) of T_{eff} (CD45⁺CD4⁺Foxp3⁻ cells) isolated from LN and spinal cord of DEREG mice two days after DTx or PBS treatment ($n = 11$ mice per group, pooled data from three independent experiments). (H) Mean frequency (\pm SEM) of IFN γ ⁺ cells in T_{eff} isolated from LN and spinal cord of DEREG mice two days after DTx or PBS treatment ($n = 5$ mice per group, representative data from three independent experiments) (I) EdU was injected i.p. one day after DTx or PBS treatment and 16 hours later lymphocytes were isolated and stained for EdU. Mean frequency (\pm SEM) of EdU⁺ cells within T_{eff} ($n = 13-14$ mice per group, pooled data from four independent experiments). (* $P < 0.05$, ** $P < 0.01$, t-test).

T cells (T_{eff}) in the draining lymph nodes (LN), as well as in the spinal cord, using flow cytometry. Interestingly, lymph nodes and spinal cord of T_{reg} -depleted mice contained significantly elevated numbers of T_{eff} (defined as CD45⁺CD4⁺Foxp3⁻ T cells) compared to control mice (Figure 2G). In addition, DTx-treated mice displayed higher frequencies of pro-inflammatory cytokine IFN γ -secreting T_{eff} in the CNS and LN (Figure 2H). In contrast, we detected similar frequencies of IL-17⁺ T_{eff} in both groups. We also did not observe differences in the percentage of activated CD25⁺CD44^{high} T_{eff} in DTx-

treated mice (Additional file 1: Figure S2). Therefore, the exacerbated EAE pathology observed in T_{reg} -depleted mice could be attributed to increased fraction of IFN γ -producing T_{eff} in the CNS.


T_{reg} are known to suppress the proliferation and activation of T_{eff} cells through multiple mechanisms [1]. Lack of functional T_{reg} results in a lymphoproliferative disease, as in *scurfy* mutant mice [30]. Similar fatal lymphoproliferative disease was observed after chronic depletion of T_{reg} in adult and neonatal mice [5,6]. To determine if the elevated numbers of T_{eff} were a result

of increased T cell proliferation, we assessed the *in vivo* proliferation of T_{eff} in the presence or absence of T_{reg} . One day after the DTx or PBS treatment of immunized DEREg mice, we injected EdU (5-ethynyl-2'-deoxyuridine), a thymidine analogue which is readily incorporated into cellular DNA during DNA replication, and examined the EdU incorporation in T cells by flow cytometry (Figure 2I). The fraction of EdU⁺ T_{eff} was significantly higher in both LN and the spinal cord of DTx-treated mice compared to control mice, suggesting that the T_{eff} proliferation during EAE is enhanced in the absence of T_{reg} .

Since we observed an increased proliferation of T_{eff} in the CNS, we focused on the role of IL-2, a pivotal cytokine for T cell proliferation. T_{reg} express high levels of high affinity IL-2 receptor α (CD25), thereby restricting the availability of IL-2 by direct consumption to restrain the activation of proliferating T cells [31]. We hypothesized that the enhanced T_{eff} proliferation that we observed after elimination of T_{reg} could be attributed to increased availability of IL-2. To test this hypothesis, we quantified the IL-2 protein levels in LN and spinal cord

tissue extracts from T_{reg} -depleted and T_{reg} -intact mice with EAE. However, both groups exhibited similar levels of IL-2 (Additional file 1: Figure S3A). Furthermore, administration of anti-IL-2 blocking antibodies in parallel with DTx treatment did not prevent EAE exacerbation (Additional file 1: Figure S3B). These findings suggest that IL-2 deprivation is not a major mechanism used by T_{reg} to control T_{eff} proliferation *in vivo* within the CNS during EAE.

We considered the possibility of direct or indirect interactions of T_{reg} with T_{eff} and APCs to mediate suppression of T_{eff} in the CNS during EAE recovery. Previous 2-photon imaging studies in LN have shown that T_{reg} can limit the contacts between T_{eff} and DCs [21-23]. However, the effect of T_{reg} on the migratory behavior of T_{eff} within the CNS during EAE is not known. We sought to investigate how the ablation of T_{reg} can affect the dynamic behavior of T_{eff} in the CNS using intravital two-photon imaging. To this end, we crossed T-Red mice, in which T cells express the red fluorescent protein dsRedII [32], to DEREg mice. Subsequently, we treated MOG-immunized



T-Red x DEREg mice with DTx or PBS at the peak of EAE and performed intravital two-photon imaging in the spinal cord meninges.

Cell tracking of the dsRedII-expressing T_{eff} revealed that T_{eff} displayed more confined trajectories in the CNS of DTx-treated mice than PBS-treated mice (Figure 3A,B). Indeed, analysis of the T_{eff} tracks showed that the cells had significantly reduced mean velocity and linearity index compared to the control animals in the CNS (Figure 3C,D). In parallel, the stationary phase of T_{eff} was increased (Figure 3E). Collectively, these findings suggest that the absence of T_{reg} results in decreased motility of T_{eff} , which indicates enhanced interactions with potential APCs within the inflamed spinal cord meninges.

In summary, using 2-photon imaging, we showed that T_{reg} exert dynamic control over T_{eff} within the CNS during effector phase of EAE. This finding doesn't exclude additional actions mediated by T_{reg} in the periphery. Our results are in agreement with many reports which showed that ablation of T_{reg} population (by treatment with anti-CD25 antibody) exacerbates EAE [9,14-16]. However, a major disadvantage of this approach is that CD25 is not a T_{reg} -specific marker, but is also expressed by activated T_{eff} complicating the interpretation of these findings. Our approach using DEREg mice circumvents these issues by specifically timed depletion of T_{reg} . This is also a first study in an active EAE which uses specific T_{reg} depletion. Our results are compatible with a recent report which showed that selective Treg depletion resulted in an increased incidence and accelerated disease onset in a spontaneous EAE model [19].

While the importance of Treg during CNS autoimmunity is unequivocally shown, where and in which phase of the disease they are important is not clear. The main conclusion from our study is that the T_{reg} exert their regulatory control over T_{eff} within the CNS in addition to their known peripheral effects. At first glance, our results are in contrast to a report by Korn *et al.*, which suggested that regulatory T cells accumulate in the CNS but are unable to control CNS infiltrating T_{eff} during peak of the disease [8]. The conclusions were drawn based on the inability of CNS derived T_{reg} to suppress T_{eff} proliferation. We, however, have followed the behavior of T_{eff} cells in their "native" environment. Moreover, several studies reported that natural recovery from EAE correlating with increasing T_{reg} numbers suggests that T_{reg} are essential to mediate recovery [8-10]. Concerning the potential mode of action, we observed that the exacerbation of EAE was preceded by an increase in the numbers of T_{eff} due to local proliferation in the absence of T_{reg} . Earlier reports using two-photon microscopy have demonstrated that $CD4^+CD25^-$ T cells established longer contacts with DCs in lymph node in

the absence of T_{reg} (defined as $CD4^+CD25^+$ T cells), while in T_{reg} -sufficient environment these contacts were inhibited [22,23]. Moreover, T_{reg} have been recently described to suppress the T cell movements in the LN during EAE in a PSGL-1-dependent mechanism [21]. Our results show that there is an increase in the motility of T_{eff} in T_{reg} -depleted mice and there was an increase in the stationary phase of T_{eff} , indicating increased contacts with APCs in the CNS. In conclusion, our findings suggest that T_{reg} are indispensable for recovery from EAE through their actions within and outside of the CNS.

Additional file

Additional file 1: Figure S1. DTx injection does not affect EAE course in non-transgenic mice. Mean clinical score (\pm SEM) of mice following immunization and DTx or PBS treatment (day 4 post EAE onset). ($n = 5-6$ mice per group, representative data from two independent experiments). **Figure S2.** Expression of IL-17 and T cell activation markers in T_{reg} -depleted mice. (A) Mean frequency (\pm SEM) of IL-17⁺ cells in T_{eff} isolated from LN and spinal cord of DEREg mice two days after DTx or PBS treatment ($n = 5$ mice per group, representative data from three independent experiments) (B) Mean frequency (\pm SEM) of $CD25^+CD44^{high}$ cells within T_{eff} isolated from LN and spinal cord of DEREg mice two days after DTx or PBS treatment ($n = 8$ mice per group, pooled data from two independent experiments). **Figure S3.** T_{reg} do not use IL-2 deprivation to limit T_{eff} proliferation. (A) IL-2 protein levels (\pm SEM) in LN and spinal cord of DEREg mice two days after DTx or PBS treatment ($n = 5$ mice per group, pooled data from two independent experiments). (B) Mean clinical score (\pm SEM) of mice following immunization and DTx treatment (day 4 post EAE onset) as well as anti-IL2 antibody treatment on days 4 and 6 post EAE onset (see arrow) ($n = 3-4$ mice per group, representative data from two independent experiments).

Competing interests

The authors declare that they have no competing interests.

Acknowledgments

We thank Irene Arnold-Ammer, Sabine Kosin and Birgit Kunkel for technical support. We thank Ingo Bartholomäus for providing analysis tools for imaging data. We thank Tim Sparwasser for providing DEREg mice. This work was funded by the Hertie foundation, SFB/CRC 128 (Deutsche Forschungsgemeinschaft), KKNMS (Klinische Kompetenznetz Multiple Sklerose; BMBF) and the Max Planck Society. H.W. is an incumbent of a Hertie senior professorship. N.K. is supported by the Novartis Foundation for Therapeutic Research and LMU Munich.

Author details

¹Department of Neuroimmunology, Max Planck Institute of Neurobiology, Am Klopferspitz 18, 82152 Martinsried, Germany. ²Institute of Clinical Neuroimmunology, Ludwig-Maximilians-University, Marchioninstr. 15, 81377 Munich, Germany.

Received: 17 November 2014 Accepted: 18 November 2014

Published online: 05 December 2014

References

1. Josefowicz SZ, Lu LF, Rudensky AY (2012) Regulatory T cells: Mechanisms of differentiation and function. *Annu Rev Immunol* 30:531–564. doi:10.1146/annurev.immunol.25.022106.141623
2. Bennett CL, Christie J, Ramsdell F, Brunkow ME, Ferguson PJ, Whitesell L, Kelly TE, Saulsbury FT, Chance PF, Ochs HD (2001) The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. *Nat Genet* 27:20–21
3. Brunkow ME, Jeffery EW, Hjerrild KA, Paepfer B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F (2001) Disruption of a new forkhead/winged-helix protein, scurf, results in the fatal

- lymphoproliferative disorder of the scurfy mouse. *Nat Genet* 27:68–73. doi:10.1038/83784
4. Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. *Nat Immunol* 4:330–336. doi:10.1038/ni904
 5. Kim JM, Rasmussen JP, Rudensky AY (2007) Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. *Nat Immunol* 8:277–284. doi:10.1038/ni1428
 6. Lahl K, Loddenkemper C, Drouin C, Freyer J, Arnason J, Eberl G, Hamann A, Wagner H, Huehn J, Sparwasser T (2007) Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. *J Exp Med* 204:57–63
 7. Krishnamoorthy G, Holz A, Wekerle H (2007) Experimental models of spontaneous autoimmune disease in the central nervous system. *J Mol Med* 85:1161–1173. doi:10.1007/s00109-007-0218-x
 8. Korn T, Reddy J, Gao WD, Bettelli E, Awasthi A, Petersen TR, Bäckström BT, Sobel RA, Wucherpfennig KW, Strom TB, Oukka M, Kuchroo VK (2007) Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. *Nat Med* 13:423–431
 9. McGeachy MJ, Stephens LA, Anderson SM (2005) Natural recovery and protection from autoimmune encephalomyelitis: Contribution of CD4+CD25+ regulatory cells within the central nervous system. *J Immunol* 175:3025–3032
 10. O'Connor RA, Malpass KH, Anderson SM (2007) The inflamed central nervous system drives the activation and rapid proliferation of Foxp3+ regulatory T cells. *J Immunol* 179:958–966
 11. Kohm AP, Carpentier PA, Anger HA, Miller SD (2002) Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. *J Immunol* 169:4712–4716
 12. Mekala DJ, Alli RS, Geiger TL (2005) IL-10-dependent infectious tolerance after the treatment of experimental allergic encephalomyelitis with redirected CD4+CD25+ T lymphocytes. *Proc Natl Acad Sci U S A* 102:11817–11822
 13. Stephens LA, Malpass KH, Anderson SM (2009) Curing CNS autoimmune disease with myelin-reactive Foxp3(+) Treg. *Eur J Immunol* 39:1108–1117
 14. Gärtner D, Hoff H, Gimsa U, Burmester GR, Brunner-Weinzierl MC (2006) CD25 regulatory T cells determine secondary but not primary remission in EAE: Impact on long-term disease progression. *J Neuroimmunol* 172:73–84
 15. Montero E, Nussbaum G, Kaye JF, Perez R, Lage A, Ben-Nun A, Cohen IR (2004) Regulation of experimental autoimmune encephalomyelitis by CD4+, CD25+ and CD8+ T cells: analysis using depleting antibodies. *J Autoimmun* 23:1–7
 16. Zhang X, Koldzic DN, Izikson L, Reddy J, Nazareno RF, Sakaguchi S, Kuchroo VK, Weiner HL (2004) IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. *Int Immunol* 16:249–256
 17. Hori S, Haurly M, Coutinho A, Demengeot J (2002) Specificity requirements for selection and effector functions of CD25+ regulatory T cells in anti-myelin basic protein T cell receptor transgenic mice. *Proc Natl Acad Sci U S A* 99:8213–8218
 18. Olivares-Villagómez D, Wang Y, Lafaille JJ (1998) Regulatory CD4+ T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis. *J Exp Med* 188:1883–1894
 19. Lowther DE, Chong DL, Ascough S, Ettore A, Ingram RJ, Boynton RJ, Altmann DM (2013) Th1 not Th17 cells drive spontaneous MS-like disease despite a functional regulatory T cell response. *Acta Neuropathol* 126:501–515. doi:10.1007/s00401-013-1159-9
 20. Reddy J, Waldner H, Zhang XM, Illés Z, Wucherpfennig KW, Sobel RA, Kuchroo VK (2005) CD4+CD25+ regulatory T cells contribute to gender differences in susceptibility to experimental autoimmune encephalomyelitis. *J Immunol* 175:5591–5595
 21. Angiari S, Rossi B, Piccio L, Zinselmeyer BH, Budui S, Zenaro E, Della Bianca V, Bach SD, Scarpini E, Bolomini-Vittori M, Piacentino G, Dusi S, Laudanna C, Cross AH, Miller MJ, Constantin G (2013) Regulatory T cells suppress the late phase of the immune response in lymph nodes through P-selectin glycoprotein ligand-1. *J Immunol* 191:5489–5500. doi:10.4049/jimmunol.1301235
 22. Tadokoro CE, Shakhari G, Shen SQ, Ding Y, Lino AC, Maraver A, Lafaille JJ, Dustin ML (2006) Regulatory T cells inhibit stable contacts between CD4+ T cells and dendritic cells in vivo. *J Exp Med* 203:505–511
 23. Tang QZ, Adams JY, Tooley AJ, Bi MY, Fife BT, Serra P, Santamaria P, Locksley RM, Krummel MF, Bluestone JA (2006) Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. *Nat Immunol* 7:83–92
 24. Onishi Y, Fehérvári Z, Yamaguchi T, Sakaguchi AY (2008) Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. *Proc Natl Acad Sci U S A* 105:10113–10118
 25. Mempel TR, Pittet MJ, Khaiaze K, Weninger W, Weissleder R, von Boehmer H, von Andrian UH (2006) Regulatory T Cells Reversibly Suppress Cytotoxic T Cell Function Independent of Effector Differentiation. *Immunity* 25:129–141. http://dx.doi.org/10.1016/j.immuni.2006.04.015
 26. Domingues HS, Mues M, Lassmann H, Wekerle H, Krishnamoorthy G (2010) Functional and pathogenic differences of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. *PLoS One* 5:e15531. doi:10.1371/journal.pone.0015531
 27. Berer K, Mues M, Koutrolas M, Al Rasbi Z, Boziki M, Johner C, Wekerle H, Krishnamoorthy G (2011) Commensal microbiota and myelin oligodendrocyte glycoprotein cooperate to trigger autoimmune demyelination. *Nature* 479:538–541. doi:10.1038/nature10554
 28. Mues M, Bartholomaeus I, Thestrup T, Griesbeck O, Wekerle H, Kawakami N, Krishnamoorthy G (2013) Real-time in vivo analysis of T cell activation in the central nervous system using a genetically encoded calcium indicator. *Nat Med* 19:778–783. doi:10.1038/nm.3180
 29. Pesic M, Bartholomaeus I, Kyrtasous NI, Heissmeyer V, Wekerle H, Kawakami N (2013) 2-photon imaging of phagocyte-mediated T cell activation in the CNS. *J Clin Invest* 123:1192–1201. doi:10.1172/JCI67233
 30. Godfrey VL, Wilkinson JE, Rinchik EM, Russell LB (1991) Fatal lymphoreticular disease in the scurfy (sf) mouse requires T cells that mature in the sf thymic environment: Potential model for thymic education. *Proc Natl Acad Sci U S A* 88:5528–5532
 31. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ (2007) CD4+CD25+ Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. *Nat Immunol* 8:1353–1362. doi:10.1038/ni1536
 32. Pittet MJ, Mempel TR (2008) Regulation of T-cell migration and effector functions: insights from in vivo imaging studies. *Immunol Rev* 221:107–129

doi:10.1186/s40478-014-0163-1

Cite this article as: Koutrolas *et al.*: Treg cells mediate recovery from EAE by controlling effector T cell proliferation and motility in the CNS. *Acta Neuropathologica Communications* 2014 **2**:163.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

